Prospective multiparametric CMR characterization and MicroRNA profiling of anthracycline cardiotoxicity: A pilot translational study

Harries, Iwan; Biglino, Giovanni; Ford, K L; Nelson, Martin; Rego, Gui; Srivastava, Prashant K.; Williams, Mark; Berlot, B; Gárate, Estefania De; Baritussio, Anna; Liang, Kate; Baquedano, Mai; Chavda, Nikesh; Lawton, Christopher; Shearn, Andrew I U; Otton, Sophie; Lowry, Lisa; Nightingale, Angus; Plana, Juan Carlos; Marks, David; Emmanueli, Costanza; Bucciarelli-Ducci, Chiara

doi:10.1016/j.ijcha.2022.101134

Search citation statements

Order By: Relevance

Paper Sections

Select...

Circulating Mirna In Response To Anthracyclines In Patients2

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 50 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 55 Additionally, increased miR-181a-3p levels at baseline, before the start of chemotherapy, were associated with less LVEF recovery 6 months after the end of treatment in adults. 57 Moreover, in adult patients with breast cancer, a decline in miR-181b/c levels was associated with a rise in cTnI and/or cTnT. 49 …”

Section: Circulating Mirna In Response To Anthracyclines In Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity

Boen,

Cherubin,

Franssen

et al. 2024

JACC: CardioOncology

View full text Add to dashboard Cite

Section: Circulating Mirna In Response To Anthracyclines In Patientsmentioning

confidence: 99%

“… 55 In adults with lymphoma, miR-221-3p was reduced at baseline in patients with poor recovery of LVEF after the end of DOX treatment, compared to those with good recovery. 57 …”

Section: Circulating Mirna In Response To Anthracyclines In Patientsmentioning

confidence: 99%

Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity

Boen,

Cherubin,

Franssen

et al. 2024

JACC: CardioOncology

View full text Add to dashboard Cite

Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods

Kuang,

Kong,

Yan

et al. 2024

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statementCardio-oncology is an emerging interdisciplinary field dedicated to the early detection and treatment of adverse cardiovascular events associated with anticancer treatment, and current clinical management of anticancer-treatment-related cardiovascular toxicity (CTR-CVT) remains limited by a lack of detailed phenotypic data. However, the promise of diagnosing CTR-CVT using deep phenotyping has emerged with the development of precision medicine, particularly the use of omics-based methodologies to discover sensitive biomarkers of the disease. In the future, combining information produced by a variety of omics methodologies could expand the clinical practice of cardio-oncology. In this review, we demonstrate how omics approaches can improve our comprehension of CTR-CVT deep phenotyping, discuss the positive and negative aspects of available omics approaches for CTR-CVT diagnosis, and outline how to integrate multiple sets of omics data into individualized monitoring and treatment. This will offer a reliable technical route for lowering cardiovascular morbidity and mortality in cancer patients and survivors.

show abstract

Prospective multiparametric CMR characterization and MicroRNA profiling of anthracycline cardiotoxicity: A pilot translational study

Cited by 2 publications

References 50 publications

Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity

Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity

Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods

Contact Info

Product

Resources

About